Pathogenesis and Risk Factors
There are various theories as to how CSDH develops. According to one theory, the cause is rupturing of bridging veins that leak fl uid into the subdural space, whereas another theory suggests that the appearance of microtears in the dura-arachnoid border layer, with subsequent leakage of cerebrospinal fluid (CSF) in the newly created space, creates an infl ammatory reaction.
Various conditions are associated with CSDH, minor trauma most commonly. Minor trauma can trigger subdural leakage and hematoma formation. Brain atrophy in the elderly population is an important contributing factor to development of CSDH. This makes the bridging veins prone to tear. In elderly patients, the "virtual" subdural space is much larger compared with a nonatrophic cerebrum. Coagulopathy is another important risk factor for CSDH. This correlates with a rise in incidence related to contemporary anticoagulant use. Coagulopathy may also be caused by alcohol abuse and liver failure, which are less frequent. In a previously published study, anticoagulant/ antiplatelet use was present in 50% of 500 surgically treated patients.
As mentioned, CSDH may develop from an acute subdural hematoma. CSDH is often surrounded by an inner and an outer membrane. These membranes probably arise as a proliferation reaction from a rupture of the dural border layer. We explain this in the next section.
Pathophysiology

A Coagulopathic State Maintains and Promotes the Subdural Bleeding
Virchow first referred to CSDH in 1857, namely as pachymeningitis haemorrhagica interna. Coagulopathy and hyperfi brinolysis in the subdural fl uid expand the hematoma through rebleeding and impaired clotting. In a mature CSDH, it has been demonstrated that the subdural fl uid contains low levels of coagulation factors and high levels of coagulation inhibitors. Next to the hypocoagulable state, the outer membrane produces high levels of tissue plasminogen activator (TPA). TPA transforms plasminogen into plasmin, which degrades fibrin. The subdural fluid contains low concentrations of plasminogen activator inhibitor. This tilts the balance in favor of production of TPA. Hyperfi brinolysis causes fibrinogen to degrade into factors that act as anticoagulants and vasodilators. This contributes to maintenance and growth of the hematoma.
Thrombomodulin (TM) levels in the subdural fl uid are usually higher than those in peripheral blood. TM is a thrombin receptor that inhibits clotting by forming a complex with thrombin and activated protein C. In case of endothelial injury such as in CSDH, the TM levels rise. This suggests continuous damage of sinusoidal vessels. TM also inhibits hemostatic thrombus formation in the hematoma, leading to hematoma expansion. The injured blood vessel causes platelet accumulation at the damaged site to form a hemostatic plug. Plasma coagulation proteins are activated to initiate secondary hemostasis. Clotting follows by the extrinsic and intrinsic pathways. The intrinsic clotting system involves factors VIII, IX, XI, and XII, which have been demonstrated to be reduced in the hematoma fl uid of CSDH.
Activated protein C and antithrombin III are the most important inhibitors of coagulation in blood plasma, and these levels are reduced in subdural fl uid as well. The low levels of the latter suggest that decreased levels of clotting factors are caused by rapid consumption, which refl ects the attempt at coagulation. The hematoma expands because of defective clot formation within the capsule. Thus, the regulatory mechanisms for coagulation and fi brinolysis are disturbed, which causes uncontrolled hemorrhaging.
Role of Infl ammation in Hematoma and Membrane Formation
There are many scientific reports of the presence of infl ammatory molecules within hematoma. Among these molecules, the proinfl ammatory platelet-activating factor (PAF) is important. It stimulates chemotaxis and TPA. PAF increases vascular permeability and causes degranulation of eosinophils. Compared with venous blood, a higher concentration of the proinfl ammatory interleukins IL-2R, IL-5, IL-7, IL-8, and IL-6 and the anti-infl ammatory cytokines IL-10 and IL-13 can be found in the hematoma. Table 1 lists the function of some important cytokines. The high level of IL-6 is explained by its induction in fi broblasts and epithelial cells by thrombin. The concentrations of the proinfl ammatory cytokines tumor necrosis factor (TNF)-α, IL-1β, IL-2, and IL-4 are lower in the hematoma than in blood. The cells that produce cytokines (eg, eosinophils, lymphocytes, monocytes, neutrophils, basophils, and mast cells) can be found in hematoma capsules and fl uid.
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The kallikrein-kinin system also plays a role in the pathophysiology of CSDH: prekallikrein in the hematoma is transformed to kallikrein by factor XII. Kallikrein converts high-molecular-weight kininogen into bradykinin, the most potent infl ammatory agent in the human body. This agent stimulates vascular permeability leading to more hematoma fl uid. In summary, the concentration of proinfl ammatory cytokines in the hematoma fluid is higher than the concentration of anti-infl ammatory cytokines. This leads to a sustained infl ammatory reaction.
Membranes
In a mature state, the hematoma is surrounded by an inner and an outer membrane. The inner membrane forms later than the outer membrane, usually when the latter has a thickness of 1 to 2 mm. The inner membrane is not vascularized and does not play an important role in the pathophysiology of CSDH. Its main role is bordering the hematoma on the arachnoid side. Studies suggest that eosinophils proliferate and degranulate inside the membranes and influence the inflammatory process. Because of the presence of immaturely developed blood vessels, smooth muscle, eosinophils, myofi broblasts, and connective tissue, the outer membrane contributes to hematoma maintenance. The neovasculature partially regulates hematoma growth and retention. The membrane exhibits capillaries that are widened (up to 1000 μm) and proliferative. One of the proteins enhancing the proliferation of these fragile vessels is vascular endothelial growth factor (VEGF). VEGF enhances vascular permeability, which results in an increased transfer of plasma components into the hematoma and disrupts endothelial gap junctions. Because of the high permeability of macrocapillaries and the large gap junctions, exudation of intravascular content is possible.
Subdural Hematoma Versus Subdural Effusion
It is important to distinguish between subdural hematoma and subdural effusion. The hematoma fl uid originates from blood and has a high concentration of erythrocytes. In patients with subdural effusion however, there is an accumulation of CSF in the subdural space. This is not surrounded by neomembranes. The accumulation is caused by CSF leaks, which in return can lead to CSDH, as described in the pathogenesis section.
Diagnosis
Epidemiology
CSDH has a peak incidence in the sixth and seventh decades of life. This is partly attributable to brain atrophy in elderly people. The space between the brain and skull increases from 6% to 11% of the total intracranial space. Moreover, elderly persons have a higher susceptibility to (minor) trauma, which is a major cause of CSDH. In addition, because of the high prevalence of cardiovascular disease in the elderly population, the use of anticoagulants and antiplatelet therapies is frequent (9%-41%) and is a risk factor for development of CSDH. Patients with bilateral hematomas are more often on antiplatelet or anticoagulant therapy than patients with a unilateral hematoma.
Clinical Presentation
CSDH is often called the "great imitator" because there are no specifi c symptoms belonging only to this disease. For example, the differential diagnosis of CSDH includes acute stroke in some patients. Whereas anticoagulants are an accepted treatment for stroke, CSDH is a contraindication to use of anticoagulants. This illustrates the importance of excluding CSDH if it is suspected.
The most common symptoms of CSDH are headache, neurologic motor defi cits, lowered consciousness level, and an altered cognitive state. Vomiting and symptoms of high intracranial pressure are more common in younger patients. Headache can be accompanied by nausea or vomiting. Nausea, vomiting, headache, and an unsteady gait are more prevalent in bilateral hematomas. Speech disorder is more prevalent in unilateral hematomas, especially on the left side. The neurologic motor defi cits and altered cognitive state, which are often present in elderly patients, may mimic dementia or cerebrovascular disease. Therefore, CSDH can easily be misdiagnosed. The motor defi cits reported are often mild, but t h e y may become more severe over time. Less commonly, patients with CSDH experience epileptic insults, transient neurologic defi cits, isolated neurologic defi cits, extrapyramidal symptoms, and frequent falls.
Imaging
Most often, CSDH is diagnosed by use of CT. This is a safe and, compared with MRI, relatively cheap method of imaging. A CT scan in a patient with CSDH can roughly demonstrate one of the following 3 distinct forms: (1) a hyperdense hematoma; (2) an isodense hematoma; or (3) a hypodense hematoma. Hyperdense hematomas are usually relatively recent hematomas, with active (re)bleeding components because fresh blood with high protein exudation rates has a high density on a CT scan. Hypodense hematomas are older hematomas. From 2 to 4 weeks and onward, hematomas have been demonstrated to become less dense than the brain parenchyma. Older hematomas with components pertaining to rebleeding may appear as mixed dense or isodense. The problem with patients with the latter form of hematoma is that the diagnosis of CSDH is easily missed. Figure 1 shows 5 CT scans with different presentations of CSDH. CT scans with enhanced ion concentration are highly sensitive for diagnosis of isodense hematomas. MRI can detect CSDH that appears isodense on CT, even in patients without midline shift. On MRI, septa within the hematoma can also be visualized, which can be important for treatment. In general, CSDH appears hyperintense compared with normal brain tissue on both T1-weighted and T2-weighted MRI sequences.
Conclusion
The incidence of CSDH is increasing because of the aging population and common use of antithrombotic therapies. Therefore, it is important to be alert for this condition when patients, especially older patients, present with headache or other nonspecifi c neurologic symptoms. Part II of this series will discuss surgical and conservative treatment options for patients with CSDH.
